NCT06508684View on ClinicalTrials.gov

Current Status of BTKi Treatment for CLL/SLL in China

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

February 12, 2025

Study Completion Date

July 12, 2025

Conditions
CLL/SLL
Interventions
DRUG

BTK inhibitor

BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib

Trial Locations (1)

210029

RECRUITING

Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER